The Institute for Translational Neuroscience (ITN) represents a unique approach to identifying and developing new medications novel therapeutics for drug and alcohol abuse, PTSD, stress, anxiety, impulsivity, and depression and on understanding the neural mechanisms responsible for these disorders. The ITN focuses on translational neuroscience research that rests at the intersection of psychology, behavioral pharmacology, and neuroanatomy. The ITN includes investigators with track records conducting research in these areas and includes a team that provide support for regulatory approvals, data sharing, study design and outreach to partners for ITN projects, facilitated through centralized ITN core support facilities. Over the past several years, the ITN team have worked on the development of psychedelic therapeutics for a range of psychiatric conditions including MDMA for PTSD and psilocybin for demoralization and depression.